The aims of the current study were to determine the prevalence and incidence of prescription opioid analgesic use in Australia and compare the characteristics of people with and without cancer initiating prescription opioid analgesics.
Introduction
Opioid use has increased rapidly in Australia and internationally over the past two decades [1, 2] . This increase is mainly attributable to greater opioid prescribing for chronic noncancer pain (CNCP) [3, 4] . Although the effectiveness of opioids has been established for acute [5] and cancer [6] pain, the long-term effectiveness in CNCP is uncertain [7] . Increasing opioid use has been associated with parallel increases in opioid-related morbidity and mortality, including dependence, hospitalizations and overdose [1, 8] .
Opioid-related deaths appear most common in people aged <50 years [8] [9] [10] . Previous work examining strong opioid initiation among concessional beneficiaries in Australia identified that oxycodone was the most commonly initiated strong opioid, and that those initiating oxycodone were younger and less likely to have cancer [11] . The Australian Pain and Opioids In Treatment (POINT) study has found that people with CNCP taking opioids have complex demographic and clinical profiles, and a long history of pain [12] . Similar complex profiles have been described internationally among people with CNCP [13] [14] [15] [16] . To date, no populationbased studies have examined the initiation of all opioid analgesics in the Australian general adult population.
Following recent declines in annual prescribing rates in the US [17] , it is unclear whether the prevalence and incidence of opioid use has changed in Australia in recent years. Additionally, comparisons of Australians who initiate opioids with and without a history of cancer have not been extensively described. Therefore, the objectives of the present study were to: (i) determine the prevalence and incidence of prescription opioid analgesic use in Australia between July 2013 and June 2017; and (ii) compare the characteristics of people with and without cancer initiating prescription opioid analgesics.
Methods

Study design and setting
We identified a nationally representative cohort of prevalent and incident opioid users between July 2013 and June 2017. Data were sourced from a random 10% sample of people who accessed subsidized medicines through Australia's Pharmaceutical Benefits Scheme (PBS). The Department of Human Services (DHS) subsidizes PBS prescriptions for Australian citizens, permanent residents and foreign visitors from countries with reciprocal healthcare agreements [18] . Two co-payment thresholds are set each year: a general copayment (A$39.50 in 2018) and a concessional co-payment amount (A$6.40 in 2018). General beneficiaries are entitled to subsidized rates on higher-cost medicines priced above a set co-payment, whereas concessional beneficiaries (e.g. pensioners and those earning a low income) pay a reduced co-payment. Since July 2012, data have been available for all under co-payment dispensings from approved community pharmacies and private hospitals, and for outpatient and discharge dispensings from public hospitals in most states and territories (except NSW and the ACT). As most opioids are under co-payment for general beneficiaries, our study period commenced in July 2013, to obtain complete capture of opioid dispensings.
Opioid prevalence and incidence
All PBS-listed opioids available during the study period were included and defined according to the World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system (Appendix Table A1 ). To obtain a 10% population sample, population data for adults aged 18-99 years from the Australian Bureau of Statistics were divided by 10 for each financial year (01 July-30 June). This was used as the denominator to determine the prevalence and incidence of opioid use [19] . To maintain confidentiality, we did not analyse data for people aged ≥100 years due to small numbers of people in this category. People with ≥1 opioid dispensing in each financial year were defined as prevalent opioid users. Therefore, prevalent users included both new (incident) users and continuous users from the previous financial years. To determine the prevalence of opioid use, the total number of opioid users was divided by the population-based denominator for each financial year. People initiating opioids were defined as those with no opioid dispensings in the 12 months prior to the opioid index date of supply. Therefore, the number of people aged 18-99 years initiating opioids was divided by the population-based denominator for each financial year to determine the incidence of use. As we used a 12-month look-back period to define initiation, it is possible that a person initiated opioids more than once throughout the 4-year study period.
Characteristics of people initiating opioids
To explore further the characteristics of people initiating opioids, and to compare these among people with and without cancer, we also examined a range of variables, including opioid characteristics, prescriber specialty, medical comorbidities and other medicine use.
Opioid characteristics. Each person's initial opioid/s were further categorized as short acting, long acting or both; and weak opioid, strong opioid or both (Appendix Table A1 ). Individuals dispensed both a weak and strong opioid on the index date were categorized as having both strong and weak opioids. Similarly, individuals dispensed both a short-acting and long-acting opioid on the index date were categorized as having both short-acting and long-acting opioids. The administration route was categorized as oral, transdermal, other (intravenous, subcutaneous or intramuscular injections, buccal, rectal) and ≥2 routes (≥2 opioids dispensed on the index date with different routes). The initial opioid dispensings were categorized as concessional or general. The total oral morphine equivalents (OMEs), in mg, dispensed on the index date was calculated using the following formula: Total OME mg dispensed = (pack strength*OME conversion factor of opioid dispensed*quantity dispensed). The OME conversion factors were adapted from published values by Nielsen et al. [20] . The total OME mg dispensed on the index date was calculated and categorized into five groups: total OME mg <100 [e.g. 10 tablets of oral oxycodone 5 mg (75 mg OME)]; 100-249 [e.g. 16 tablets of oral oxycodone 10 mg (240 mg OME)]; 250-499 [e.g. 30 tablets of oral oxycodone 10 mg (450 mg OME)]; 500-749 [e.g. 16 tablets of oral oxycodone 30 mg (720 mg OME)]; and ≥750 [e.g. 20 tablets of oxycodone 30 mg (900 mg OME)].
Prescriber specialty. The speciality of the prescriber for each opioid initiation was categorized consistently with the terminology used by the DHS [21] . For each prescription, the DHS provides a prescriber speciality code from a list of 196 codes which are included in the 10% random PBS sample. We categorized these codes into prescriber speciality of interest: general practitioner (GP) ( Medical comorbidities. Medicines dispensed 12 months prior to and on the date of initial opioid dispensing were used to identify medical conditions using the validated RxRisk-V tool [22, 23] . We mapped the RxRisk-V tool to the International Classification of Diseases, Tenth Revision (ICD-10). To group these disease categories, we matched them to ICD-10 chapter groupings, as has been done in a previous study utilizing PBS data [11] . The RxRisk-V tool identifies fewer people with cancer than the Charlson's Comorbidity Index (43.2% vs. 67.2%) [22] . Therefore, a more comprehensive indicator for cancer was used that included other antineoplastic therapies, such as hormonal cancer therapies, which were not included in the original and updated RxRisk-V tool (Appendix Table A2 ).
Previous medicine use. Use of paracetamol, pregabalin and the PBS-subsidized nonsteroidal anti-inflammatory drugs (NSAIDs) were examined in the 3 months prior to and including the day of opioid initiation, in order to determine the recent non-opioid analgesic treatment of pain. This definition is consistent with previous published studies [11] . NSAIDs were further categorized into nonselective and cyclooxygenase 2 selective (Appendix Table A1 ). Recent use of PBS-subsidized benzodiazepines (Appendix Table A1 ) was also investigated as benzodiazepines are commonly implicated in opioid overdose deaths [24] .
Statistical analyses
Characteristics are summarized as frequencies and percentages, means and standard deviations (SDs), or medians and Table 1 Incidence and prevalence of opioid use in each financial year for people with and without cancer interquartile ranges (IQRs). Pearson's chi-square test was used to compare proportions for categorical variables, and Student's t-test was used for continuous variables. The percentage distribution of types of opioids prescribed at initiation by prescriber speciality and according to age groups were presented graphically. Poisson regression was used to calculate rate ratios (RRs) for the prevalence and incidence of opioid use, comparing the period from 2013/2014 to 2016/2017. All analyses were conducted using SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA). Table 2 Baseline characteristics in the 365 days prior to, and on the day of, opioid initiation Example of initial OME of~60 mg: eight tablets of oxycodone 5 mg (60 OME mg) or 20 tablets of paracetamol/codeine 500/30 mg (60 OME mg);
initial OME of~240 mg: 16 tablets of oxycodone 10 mg (240 OME mg) or 80 tablets of paracetamol/codeine 500/30 mg (240 OME mg) ( Comorbidities. The mean (SD) number of comorbidities for all people initiating opioids was 2.7 (2.3) ( Table 2) . Among people without cancer, the mean (SD) number of comorbidities was 2.7 (2.3), compared with 4.7 (2.5) among those with cancer (P < 0001). Among all people initiating opioids, diseases of the circulatory system (36.4%), mental and behavioural disorders (26.5%) and diseases of the digestive system (24.4%) were common. Mental and behavioural disorders were more common among people with vs. without cancer (31.9% vs. 26.4%; P < 0.001), as were disorders of the circulatory system (68.1% vs. 35.9%; P < 0001) and digestive system (52.3% vs. 23.9%; P < 0.001).
Characteristics of initial opioid(s).
Paracetamol/codeine was the most commonly dispensed opioid on initiation (54.7%), followed by single-ingredient oxycodone (23.7%) and tramadol (10.8%) ( Table 3 ). The distribution of prescribed opioids by opioid type in each financial year and by age group are depicted in Figures 1 and 2 . A strong opioid was initiated in 28.7% of the cohort and 8.6% were initiated on a long-acting opioid. The proportion of people initiating strong opioids increased from 26.0% to 31.6%, and the proportion of people initiating long-acting opioids increased from 8.0% to 9.5% between 2013/2014 and 2016/2017. The majority of people (97.6%) were initiated on oral opioid formulations. Most people (60.1%) initiating opioids had less than 100 mg in total OMEs dispensed [e.g. 10 tablets of oxycodone 5 mg (75 OME mg) or 20 tablets of paracetamol/codeine 500/30 mg (60 OME mg)]. Over half of the people with cancer (55.8%) initiated a strong opioid compared with 28.2% of people without cancer (P < 0.001).
People with cancer had a median (IQR) of 150 (60-210) mg OMEs dispensed on initiation, compared with a median (IQR) of 60 (60-150) mg OMEs among people without cancer. The proportion of people dispensed total OME <250 mg did not change over the 4-year study period (Appendix Table A3 ). People with cancer were more commonly dispensed a long-acting opioid (16.5% vs. 8.4%), oxycodone (37.2% vs. 23.4%) and oxycodone/naloxone (7.8% vs. 3.1%) than those without cancer (P < 0.001).
Prior medicine use. Non-opioid analgesics were used by 36.6% of people prior to opioid initiation, with NSAIDs being the most commonly (27.5%) used non-opioid analgesic (Table 4) . Prior paracetamol (23.1% vs. 12.2%; P < 0.001) and pregabalin (6.8% vs. 3.5%; P < 0.001) use was more common among people with cancer compared with those without cancer, whereas NSAID use (27.6% vs. 21.5%; P < 0.001) was more common among people without cancer. Benzodiazepines were used by 13.2% of the cohort. Prior benzodiazepine use was more common among people with cancer than without cancer (22.6% vs. 13.0%; P < 0.001).
Figure 1
Proportion of opioids dispensed on initiation for each financial year
Figure 2
Percentage of each opioid type dispensed on initiation by age group between July 2013 and June 2017
Prescriber specialty. Approximately half of all opioid initiations were by GPs (51%) (Appendix Figure A1) . Codeine was the most commonly prescribed opioid by dental practitioners (97.7%), GPs (67.9%) and nurse practitioners (61.7%). Oxycodone was the most commonly prescribed opioid by interns (65.6%), oncology specialists (57.2%), surgical specialists (47.0%) and anaesthetic specialists and nonspecialists (43.8%) (Figure 3 ).
Discussion
This is the first study to report the prevalence and incidence of opioid use in Australian adults. Approximately 16% of the adult population use opioids each financial year, and the prevalence of opioid use increased by 0.6% over the study period. The rate of opioid initiation decreased by 2.3% over the study period, with approximately 10% of adults initiating opioids each financial year. Paracetamol/codeine, followed by single-ingredient oxycodone and tramadol, were the most commonly prescribed opioids on initiation, with codeine use declining in the previous 2 years and oxycodone use increasing. Approximately half of all opioid initiations were by GPs. Extrapolating to the total population, each year over 1.9 million adults (10%) are estimated to initiate opioids and over 3 million adults (16%) are using opioids in Australia. The prevalence of opioid use in Australia is similar to the 14% prevalence in Ontario, Canada [25] . Despite increasing prescribing rates between 2006 and 2010 in the US, annual prescribing rates declined from 81.2 to 70.6 per 100 persons between 2010 and 2015 [17] . Our results also demonstrate a decrease (2.3%) in overall opioid initiation in Australian adults since 2013/2014. In light of increasing concerns about opioid-related harms, it is encouraging that the rate of opioid initiation appears to be decreasing. However, it is not known whether the decrease in opioid initiation has translated to a decrease in harm. The total OME amount dispensed on initiation has remained relatively stable over the 4-year study period. However, the proportion of people initiating strong or long-acting opioids has increased over the same period. This is concerning because strong and long-acting opioids have been linked to harms in both the US [26] and Australia [9] . Table 4 Selected medicine use in the 3 months prior to, and on the day of, opioid initiation Therefore, future studies should investigate the impact of recent changes in opioid use on opioid-related harm in Australia. Our study supports recent calls from the Therapeutic Goods Administration for a review of current practice and policy related to opioid prescribing [27] . Previous research investigating opioid use in Australia and the US attributed the overall increase in opioid use to their increase in use for CNCP [3, 4, 28] . In our study, previous non-opioid analgesic use was higher among people with cancer compared with those without cancer. CNCP management is complex and requires individualization [29] . Although multimodal strategies for CNCP are recommended [29] , in our study only one-third of people without cancer had used non-opioid analgesics in the previous 3 months. Therefore, our results may suggest suboptimal treatment with nonopioid analgesics, particularly in those with CNCP, where opioid use should be reserved for those who are unresponsive to optimized non-opioid therapies [29, 30] . However, data were not available on non-opioid analgesics purchased over the counter and therefore may underestimate non-opioid analgesic use. Additionally, no data were available on prescriptions that were issued by prescribers but never dispensed in pharmacies (e.g. people who successfully trialled non-opioids first and decided not to fill their opioid prescription). Nevertheless, non-opioid treatment modalities should be trialled first, to reduce inappropriate long-term opioid use and minimize harm. A US study found that 5% of opioid initiators became long-term users, defined as ≥6 opioid prescriptions in the 12 months following the initiation month [16] . They also found that long-term use was, in turn, associated with a higher risk of opioid-related hospitalization [16] . A recent study in Australia, using group-based trajectory modelling to define persistent use, found that 2.6% of adults initiating opioids became persistent users over a 12-month period [31] .
In order to identify risk mitigation strategies for opioidrelated harm, we examined prescriber specialty and the characteristics of the initial opioid. We found that approximately half of all opioid initiations were by GPs. Similarly, US studies have reported that primary care specialities prescribed 44.5% of dispensed opioid prescriptions in 2012 [32] . As pain conditions account for at least 11% of all conditions managed by GPs in Australia [33] , it is not surprising that half of all opioid initiations were by GPs. Yet, previous research in the US reported that of all specialities prescribing opioids, primary care specialities were most often associated with opioid fatalities [34] . This is concerning as, although Australia has followed a similar trend to the US in opioid-related harm, to date there have been minimal regulatory, policy or programmatic shifts in response [35] . Although interns are responsible for 8.3% of all opioids initiated, we found that oxycodone was the most commonly prescribed opioid by this group (65.6%). Interns Figure 3 Percentage of opioids initiated by prescriber specialities of interest between July 2013 and June 2017. *Other category for oncology specialists:10.7% morphine, 4.8% fentanyl and 4.5% buprenorphine, tapentadol and methadone usually prescribe medicines on discharge from hospitals in Australia under the guidance of the specialty team. The proportion of interns prescribing opioids provides important information regarding opioid initiation from hospitals. However, this may be underestimated as prescriptions dispensed at hospitals in NSW and the ACT are not captured in this dataset.
Strengths and limitations
The key strength of our study was the use of data from a 10% random sample of people accessing medicines through the PBS over a period when under co-payment data were captured. Although we captured more than 80% of prescription opioid use in Australia, data on private non-PBS prescriptions and over-the-counter analgesics were not captured [27] . The subsidy of paracetamol and tapentadol has changed throughout the study period. Since January 2016, paracetamol has no longer been subsidized on the PBS. This means that the estimate of prior paracetamol use since 2016 may be an underestimate of actual use. Tapentadol was approved for listing on the PBS in November 2013. Therefore, its lower utilization compared with other opioids may reflect a slower uptake by prescribers. Additionally, opioid initiation for hospital inpatients in all States and on discharge from hospitals in NSW and the ACT were not captured in this dataset. Therefore, our study does not necessarily reflect the characteristics of all adults initiating opioids in Australia. As PBS data are based on dispensing records, we do not know whether and how the medicine was taken. In the absence of comorbidity data, we used dispensing data to identify treatment for specific medical conditions. Although we used a comprehensive list of cancer medicines, some people with cancer may not have had cancer medicines dispensed and therefore may have been misclassified. Additionally, people may have been categorized into the noncancer group if they had a first dispensing of a cancer medicine after opioid initiation. Clinical information, including the indication for opioid initiation, dose, duration and severity of pain, was not available in our dataset.
Conclusion
Rates of opioid use in Australia have remained high since 2013, with approximately 3 million adults using opioids and over 1.9 million adults initiating opioids each year. There has been a slight increase in the prevalence of opioid use but a decrease in incidence in the 4-year period between 2013 and 2017. People without cancer account for the majority of opioid use and are more likely to be initiated on short-acting and weak opioids. The proportion of people initiating on strong opioids has increased over time, reinforcing concerns about the increase in the use and harms associated with strong opioids in the community. 
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